Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine in CML with T315I Mutation
NCT00375219Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2006
- Primary completion
- Mar 2010
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in chronic myeloid leukemia (CML), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Percentage of Participants Achieving an Overall Hematologic Response at 6 months, Percentage of Participants Achieving a Major Cytogenetic Response at 6 months and 1 more. Started Sep 2006; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00375219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00375219.